Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Carcinoma, Renal Cell

Carcinoma, Renal Cell, Kidney Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Neoplasm Metastasis

Brain Neoplasms, Neoplasms

Carcinoma, Squamous Cell

Biliary Tract Neoplasms

Advanced Malignancies

Carcinoma, Hepatocellular

Hematologic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

Stomach Neoplasms

Thyroid Carcinoma, Anaplastic

Endometrial Neoplasms

Carcinoma, Hepatocellular

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Skin Neoplasms, Carcinoma, Merkel Cell

Carcinoma, Renal Cell

Carcinoma, Hepatocellular, Liver Neoplasms

Carcinoma, Hepatocellular

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Vulvar Neoplasms

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Liver Neoplasms

Carcinoma, Hepatocellular

Clinical Trials

LEAP-012

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

MK-6482-043

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

SLIDE-HCC

MK-3475-587

KEYNOTE-B98

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

KEYMAKER-U02

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

SAMURAI

EMERALD-3

CheckMate 9DW

LaPemERLA

LONGIST

MITO VULVA-01

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

REVIVE

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

FLEX-HCC